BCA-225 antibody shows a moderate to strong cytoplasmic staining reaction for breast invasive ductal carcinoma, metastatic to lymph node.
BCA-225 (Cu-18) Mouse Monoclonal Antibody
Specialties: Anatomic Pathology Breast/Gynecological Pathology Cytopathology
Updated: 2017-05-24 08:46:09
Anti-BCA-225 primary antibody labels breast cancer antigen 225 (BCA-225) in primary and metastatic breast carcinoma. BCA-225 was first identified in T47D breast carcinoma cells, but its expression in other carcinomas such as lung, kidney, ovary and endometrium has also been demonstrated.1-4 BCA-225 expression has also been found in sebaceous gland tumors.5,6
- Mesa-Tejada R, et al. Am J Pathol; 1988 130:305-14.
- Loy TS, et al. Am J Clin Pathol. 1991; 96:326-9.
- Brown RW, et al. Am J Clin Pathol. 1997; 107:12-9.
- Ma CK, et al. Am J Clin Pathol. 1993; 99:551-7.
- Ansai S, et al. J Dermatol. 1994; 21:20-4.
- Sinard, JH. Arch Ophthalmol. 1999; 117:776-83.
Specifications
- Reactivity: paraffin
- Visualization: cytoplasmic
- Control: breast carcinoma
- Dilution Range: 1:25-1:100*
Package Inserts
IFU
- IVD Rev. 4.0 (CMC22521040)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 225M-14 |
| 0.5 mL concentrate | 225M-15 |
| 1 mL concentrate | 225M-16 |
| 1 mL predilute | 225M-17 |
| 7 mL predilute | 225M-18 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 225M-14 |
| 0.5 mL concentrate | 225M-15 |
| 1 mL concentrate | 225M-16 |
| 1 mL predilute | 225M-17 |
| 7 mL predilute | 225M-18 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 225M-14 |
| 0.5 mL concentrate | 225M-15 |
| 1 mL concentrate | 225M-16 |
| 1 mL predilute | 225M-17 |
| 7 mL predilute | 225M-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate | 225M-14-RUO |
| 0.5 mL concentrate | 225M-15-RUO |
| 1 mL concentrate | 225M-16-RUO |
| 1 mL predilute | 225M-17-RUO |
| 7 mL predilute | 225M-18-RUO |
To request information on this product in additional countries, please click the button below.